Literature DB >> 18817645

Current status of gene therapy for rheumatoid arthritis.

Daniel F Gaddy, Paul D Robbins.   

Abstract

Gene therapy offers great possibilities for treating rheumatoid arthritis (RA). Traditional surgical and pharmaceutical methods of treating RA have met with limited therapeutic success and have failed to produce a cure, but the past several years have seen extensive progress toward development of a gene therapy for arthritis. Numerous vectors and therapeutic genes have been investigated in animal models of arthritis, and the potential of gene therapy to treat or manage RA has been demonstrated in several clinical studies. Gene therapy offers the possibility of overcoming many of the limitations of current biologic therapies by providing long-term, high-level localized expression of therapeutic genes, potentially in as little as a single dose. In this review, we explore the advances in gene therapy for RA and summarize the recent preclinical and clinical data. In addition, we provide an overview of vectors and targets for RA gene therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18817645     DOI: 10.1007/s11926-008-0064-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  50 in total

1.  Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV.

Authors:  L Dudus; V Anand; G M Acland; S J Chen; J M Wilson; K J Fisher; A M Maguire; J Bennett
Journal:  Vision Res       Date:  1999-07       Impact factor: 1.886

Review 2.  Clinical applications of recombinant human BMPs: early experience and future development.

Authors:  Thomas A Einhorn
Journal:  J Bone Joint Surg Am       Date:  2003       Impact factor: 5.284

3.  Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent.

Authors:  N Amos; S Lauder; A Evans; M Feldmann; J Bondeson
Journal:  Rheumatology (Oxford)       Date:  2006-03-29       Impact factor: 7.580

Review 4.  Gene therapy for arthritis: what next?

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Rheum       Date:  2006-06

5.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product.

Authors:  James M K Chan; Gilda Villarreal; Wen Wen Jin; Tony Stepan; Haim Burstein; Sharon M Wahl
Journal:  Mol Ther       Date:  2002-12       Impact factor: 11.454

8.  Healing of segmental bone defects by direct percutaneous gene delivery: effect of vector dose.

Authors:  Volker M Betz; Oliver B Betz; Vaida Glatt; Louis C Gerstenfeld; Thomas A Einhorn; Mary L Bouxsein; Mark S Vrahas; Christopher H Evans
Journal:  Hum Gene Ther       Date:  2007-10       Impact factor: 5.695

9.  IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage.

Authors:  Iñigo Izal; Carlos Alberto Acosta; Purificación Ripalda; Mikel Zaratiegui; Juan Ruiz; Francisco Forriol
Journal:  Arch Orthop Trauma Surg       Date:  2007-07-28       Impact factor: 3.067

Review 10.  Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology.

Authors:  Jason C O'Connor; Robert H McCusker; Klemen Strle; Rodney W Johnson; Robert Dantzer; Keith W Kelley
Journal:  Cell Immunol       Date:  2008-03-05       Impact factor: 4.868

View more
  1 in total

Review 1.  Nanomedicine delivers promising treatments for rheumatoid arthritis.

Authors:  Leena Kumari Prasad; Hannah O'Mary; Zhengrong Cui
Journal:  Nanomedicine (Lond)       Date:  2015-06-18       Impact factor: 5.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.